This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Allen & Hanburys Ltd

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 22/12/2011
SPC Ventolin Syrup


Go to top of the page
1. Name of the medicinal product

Ventolin Syrup


Go to top of the page
2. Qualitative and quantitative composition

Each 5 ml contains 2 mg Salbutamol (as Salbutamol Sulphate BP).


Go to top of the page
3. Pharmaceutical form

Syrup


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Ventolin syrup is indicated in adults, adolescents and children aged 2 to 12 years.

Salbutamol is a selective beta-2 adrenoceptor agonist providing short-acting (4-6 hour) bronchodilation in reversible airways obstruction. Ventolin syrup can be used in the management of asthma, bronchospasm and/or reversible airways obstruction.

Relief of bronchospasm in bronchial asthma of all types.

Ventolin syrup is suitable oral therapy for children and adults who are unable to use an inhaler device.


Go to top of the page
4.2 Posology and method of administration

Route of administration: oral

Adults

The minimum starting dose is 2mg three times a day given as 5ml syrup. The usual effective dose is 4mg (10ml syrup) three or four times a day, which may be increased to a maximum of 8mg (20ml syrup) three or four times a day if adequate bronchodilation is not obtained.

Elderly

In elderly patients or in those known to be unusually sensitive to beta-adrenergic stimulant drugs, it is advisable to initiate treatment with the minimum starting dose.

Paediatric Population

2 - 6 years: the minimum starting dose is 1mg as 2.5ml of syrup three times daily. This may be increased to 2mg as 5ml of syrup three or four times daily.

6 - 12 years: the minimum starting dose is 2mg as 5ml syrup three times daily. This may be increased to four times daily.

Over 12 years: the minimum starting dose is 2mg three times daily given as 5ml syrup. This may be increased to 4mg as 10ml syrup three or four times daily.

Ventolin is well tolerated by children so that, if necessary, these doses may be cautiously increased to the maximum dose.

For lower doses the syrup may be diluted with freshly prepared purified water BP.


Go to top of the page
4.3 Contraindications

Although intravenous salbutamol and occasionally salbutamol tablets are used in the management of premature labour, uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage, or toxaemia of pregnancy, salbutamol presentations should not be used for threatened abortion.

Ventolin oral preparations are contra-indicated in patients with a history of hypersensitivity to any of their components.


Go to top of the page
4.4 Special warnings and precautions for use

Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment including lung function testing as patients are at risk of severe attacks and even death. Physicians should consider using oral corticosteroid therapy and/or the maximum recommended dose of inhaled corticosteroid in those patients.

Patients should seek medical advice if treatment with Ventolin syrup becomes less effective.

The dosage or frequency of administration should only be increased on medical advice.

Patients taking Ventolin syrup may also be receiving short-acting inhaled bronchodilators to relieve symptoms.

Increasing use of bronchodilators in particular short-acting inhaled beta2-agonists to relieve symptoms indicates deterioration of asthma control. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual.

In this situation patients should be reassessed and consideration given to the need for increased anti-inflammatory therapy (eg. Higher doses of inhaled corticosteroids or a course of oral corticosteroid). Severe exacerbations of asthma must be treated in the normal way.

Patients should be warned that if either the usual relief with Ventolin oral preparations is diminished or the usual duration of action reduced, they should not increase the dose or its frequency of administration, but should seek medical advice.

Ventolin syrup and non-selective beta-blocking drugs, such as propranolol, should not usually be prescribed together.

Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.

Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis.

Potentially serious hypokalaemia may result from beta-2 agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids. It is recommended that serum potassium levels are monitored is such situations.

In common with other β-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

As with the majority of drugs, there is little published evidence of its safety in the early stages of human pregnancy, but in animal studies there was evidence of some harmful effects on the foetus at very high dose levels.

As salbutamol is probably secreted in breast milk its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common and common events were generally determined from clinical trial data. Rare, very rare and unknown events were generally determined from spontaneous data.

Immune system disorders

Very rare:

Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.

Metabolism and nutrition disorders

Rare:

Hypokalaemia.

Potentially serious hypokalaemia may result from beta agonist therapy.

Nervous system disorders

Very common:

Tremor.

Common:

Headache.

Very rare:

Hyperactivity.

Cardiac disorders

Common:

Tachycardia, palpitations.

Rare:

Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles

Unknown:

Myocardial ischaemia* (see section 4.4)

Vascular disorders

Rare:

Peripheral vasodilatation.

Musculoskeletal and connective tissue disorders

Common:

Muscle cramps.

Very rare:

Feeling of muscle tension.

* reported spontaneously in post-marketing data therefore frequency regarded as unknown


Go to top of the page
4.9 Overdose

The most common signs and symptoms of overdose with salbutamol are transient beta agonist pharmacologically mediated events, including tachycardia, tremor, hyperactivity and metabolic effects including hypokalaemia and lactic acidosis (see sections 4.4 and 4.8).

Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored.

Nausea, vomiting and hyperglycaemia have been reported, predominantly in children and when salbutamol overdose has been taken via the oral route.

Consideration should be given to discontinuation of treatment and appropriate symptomatic therapy such as cardio-selective beta-blocking agents in patients presenting with cardiac symptoms (e.g. tachycardia, palpitations). Beta-blocking drugs should be used with caution in patients with a history of bronchospasm.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Salbutamol is a selective beta-2 adrenoceptor agonist. At therapeutic doses it acts on the beta-2 adrenoceptors of bronchial muscle.


Go to top of the page
5.2 Pharmacokinetic properties

Salbutamol administered intravenously has a half life of 4 to 6 hours and is cleared partly renally and partly by metabolism to the inactive 4' -O-sulphate (phenolic sulphate) which is also excreted primarily in the urine. The faeces are a minor route of excretion. The majority of a dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours. Salbutamol is bound to plasma proteins to the extent of 10%.

After oral administration, salbutamol is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine. The bioavailability of orally administered salbutamol is about 50%.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that in other sections of the SmPC.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Sodium citrate

Citric acid monohydrate

Hydroxypropyl methylcellulose

Sodium benzoate

Saccharin sodium

Sodium chloride

Orange flavour IFF 17.42.8187

Purified water


Go to top of the page
6.2 Incompatibilities

None known

Ventolin syrup is sugar free. If dilution is required freshly prepared Purified Water BP should be used. The diluted mixture must be protected from light and stored below 25ºC.


Go to top of the page
6.3 Shelf life

36 months.


Go to top of the page
6.4 Special precautions for storage

Store at a temperature not exceeding 30ºC.

Protect from light.

Ventolin syrup may be diluted with freshly Purified Water BP. The diluted mixture must be protected from light and stored below 25ºC. Discard after 28 days.


Go to top of the page
6.5 Nature and contents of container

Amber glass bottle.

Closure (150ml): plastic tamper evident, child resistant or plastic child resistant or ROPP aluminium (lacquered internally and externally) with either PVdC faced EPE or LDPE faced PVdC/EPE OR LLDPE/PVdC PVC/LLDPE/EPE (single or double faced) wad.

Closure (2000ml): polypropylene cap with wadding as for 150ml.

Pack size: 150ml, 2000ml.


Go to top of the page
6.6 Special precautions for disposal and other handling

Ventolin syrup may be diluted with Purified Water BP (50%v/v). The resulting mixture should be protected from light and used within 28 days.

A 50% v/v dilution of Ventolin syrup has been shown to be adequately preserved against microbial contamination.

Admixture of Ventolin syrup with other liquid preparation is not recommended.


Go to top of the page
Administrative data

Go to top of the page
7. Marketing authorisation holder

Glaxo Wellcome UK Ltd

trading as Allen & Hanburys

Stockley Park West

Uxbridge

Middlesex, UB11 1BT


Go to top of the page
8. Marketing authorisation number(s)

PL 10949/0088


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

14 October 2005


Go to top of the page
10. Date of revision of the text

13 December 2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/106/SPC/


Active Ingredients/Generics